

Appendix 5: Papers underlying this Scoping Review

List of the 44 papers included in the review, including the reference, type of publication and a short summary of the focus of the paper is shown in the table below.

No	Reference (BMJ style)	Study design	Focus of paper
1	Abbott FM, Reichman JH. Facilitating Access to Cross-Border Supplies of Patented Pharmaceuticals: The Case of the COVID-19 Pandemic. <i>Journal of International Economic Law</i> 2020;23(3):535-61.	Article	Proposes legal mechanisms for addressing critical issues facing the international community in terms of providing equitable access to vaccines, treatments, diagnostics, and medical equipment.
2	Bollyky TJ, Gostin LO, Hamburg MA. The Equitable Distribution of COVID-19 Therapeutics and Vaccines. <i>Jama-Journal of the American Medical Association</i> 2020;323(24):2462-63. doi: 10.1001/jama.2020.6641	Viewpoint	Discusses experiences and suggestions for a future framework to the distribution of COVID-19 vaccines.
3	Choi EM. COVID-19 vaccines for low- and middle-income countries. <i>Transactions of the Royal Society of Tropical Medicine & Hygiene</i> 2021;115(5):447-56.	Review	Discusses low- and middle-income countries access COVID-19 vaccines, what is being done to distribute vaccines fairly, as well as the challenges ahead
4	DeFrancesco L. Whither COVID-19 vaccines? <i>Nature Biotechnology</i> 2020;38(10):1132-45.	Article	Insights from seven experts on the development of the COVID-19 vaccines.
5	Eccleston-Turner M. The pandemic influenza preparedness framework: A viable procurement option for developing states? <i>Medical Law International</i> 2017;17(4):227-48.	Article	Examines the Pandemic Influenza Framework and the content of the Obligations of the Company which have been secured by the World Health Organization.
6	Eccleston-Turner M, Upton H. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. <i>Milbank Quarterly</i>	Original Scholarship	Analysis of the COVAX Facility and its aim and ensure equitable availability of the vaccine in low and middle-income countries.
7	Fedson DS. Pandemic influenza and the global vaccine supply. <i>Clin Infect Dis</i> 2003;36(12):1552-61.	Article	The article explores several issues related to the global supply of vaccine during influenza pandemics
8	Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. <i>J Public Health Policy</i> 2005;26(1):4-29.	Commentary	Focuses on the trivalent vaccines currently available that contain inactivated viruses.
9	Fedson DS, Dunnill P. Commentary: From scarcity to abundance: pandemic vaccines and other agents for "have not" countries. <i>J Public Health Policy</i> 2007;28(3):322-40.	Commentary	Discusses that access to supplies of pandemic vaccine for most countries is a problem of scarcity and how to ensure the "have not" countries will get access to pandemic vaccines.
10	Felicitas H, Florencia L, Manriquez RT, et al. A matter of priority: equitable access to COVID-19 vaccines. <i>Swiss Med Wkly</i> 2021;151	Viewpoint	Highlights inequality in current vaccination rates between some high income countries (HIC) and low income countries (LIC) provides arguments for HIC to support distribution to LIC
11	Fidler DP. Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1. <i>Plos Medicine</i> 2010;7(5)	Article	Examines the diplomatic negotiations surrounding influenza virus sharing as an example of the core tensions characterizing multilateralism and emerging forms of global health governance.
12	Fidler DP. Vaccine nationalism's politics. <i>Science</i> 2020;369(6505):749.	Editorial	Discusses global politics and the burden of global equitable COVID-19 vaccine access issues, historically and now.
13	Forman R, Anderson M, Jit M, et al. Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. <i>Vaccine</i> 2020;38(39):6075-77.	Commentary	Discusses existing financing mechanisms and a proposal for vaccine development, referred to as Options Market for Vaccines (OMV).
14	Forman R, Shah S, Jeurissen P, et al. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? <i>Health Policy</i> 2021;125(5):553-67.	Review	Offers a framework for understanding remaining and new policy challenges for global vaccine campaigns against COVID-19 and potential solutions.

No	Reference (BMJ style)	Study design	Focus of paper
15	Gray G, van der Heever A, Madhi S, et al. The Scientists' Collective 10-point proposal for equitable and timeous access to COVID-19 vaccine in South Africa. <i>Samj South African Medical Journal</i> 2021;111(2):89-94.	(Guest) Editorial	Proposes a ten-point plan for equitable and timely access to COVID-19 vaccine in South Africa.
16	Guzman J, Hafner T, Maiga LA, et al. COVID-19 vaccines pricing policy options for low-income and middle- income countries. <i>BMJ Global Health</i> 2021;6(3):03.	Commentary	Discusses four pricing strategies to address high prices and obtain COVID-19 vaccines (and other medical products) at affordable rate.
17	Herlitz A, Lederman Z, Miller J, et al. Just allocation of COVID-19 vaccines. <i>BMJ Global Health</i> 2021;6(2):02.	Editorial	Offers three suggestions to strengthen how to achieve the greatest health impact with authorized COVID-19 vaccines.
18	Iacobucci G. Covid-19: How will a waiver on vaccine patents affect global supply? <i>BMJ</i> 2021;373:n1182.	News analysis	Presents responses from experts and organizations after Biden administration (US) announced to support a proposal to waive patents on covid-19 vaccines.
19	Kamradt-Scott A, Lee K. The 2011 Pandemic Influenza Preparedness Framework: Global Health Secured or a Missed Opportunity? <i>Political Studies</i> 2011;59(4):831-47.	Article	Investigates the diplomatic negotiations surrounding influenza virus sharing, and evaluates the Pandemic Influenza Preparedness (PIP) framework.
20	Kupferschmidt K. Global plan seeks to promote vaccine equity, spread risks. <i>Science</i> 2020;369(6503):489-90.	News	Discusses the COVAX facility and its challenges.
21	Liu Y, Salwi S, Drolet BC. Multivalued ethical framework for fair global allocation of a COVID-19 vaccine. <i>Journal of medical ethics</i> 2020;46(8):499-501.	Article	Analyses and synthesizes the ethical considerations of four allocation paradigms: ability to develop or purchase; reciprocity; ability to implement; and distributive justice.
22	The Lancet. Global governance for COVID-19 vaccines. <i>Lancet (London, England)</i> 2020;395(10241):1883.	Editorial	Discusses the COVID-19 vaccine bidding war and the necessary global level arrangements to for development, finance, production, and distribution.
23	The Lancet. Access to COVID-19 vaccines: looking beyond COVAX. <i>Lancet</i> 2021;397(10278):941.	Editorial	Calls for a strong political leadership to support equitable access to vaccines
24	McAdams D, McDade KK, Ogbuogi O, et al. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective. <i>BMJ Global Health</i> 2020;5(11):11.	Commentary	Discusses how maximizing the benefit of bilateral deals to support COVAX, and explores how such deals can improve the global supply of vaccines.
25	McMahon A. Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance. <i>Journal of Medical Ethics</i> 2020;30:30.	Current controversy	Discusses the role of patents and highlights that during the COVID-19 pandemic the power of patent holders should be questioned.
26	Nhamo G, Chikodzi D, Kunene HP, et al. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs. <i>Global Public Health</i> 2021;16(3):319-39.	Article	Discusses the 2030 Agenda for Sustainable Development and calls stakeholders for their continued support to Gavi and COVAX 'to leave no one behind' and eliminate inequalities.
27	Pagliusi S, Hayman B, Jarrett S. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report. <i>Vaccine</i> 2021;39(18):2479-88.	Meeting Report	Summary of a meeting where public and private sector participants presented challenges and opportunities related to vaccine R&D, supply chain, global policies, financing, health objectives, and supporting access for LMIC.
28	Phelan AL, Eccleston-Turner M, Rourke M, et al. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. <i>Lancet</i> 2020;396(10254):800-02.	Commentary	Discusses role of law on equitable access to COVID-19 vaccines, highlighting challenges of bilateral agreements, advanced purchasing, and COVAX.
29	Rourke MF. Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements. <i>Milbank Q</i> 2019;97(1):91-112.	Article	Analyses the PIP Framework, its Standard Material Transfer Agreements (SMTAs), and secondary sources to determine whether the PIP Framework will effectively function as an access and benefit-sharing (ABS) instrument during an influenza pandemic.

No	Reference (BMJ style)	Study design	Focus of paper
30	Ruscio BA, Hotez P. Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response. <i>Vaccine</i> 2020;38(50):7880-82.	Commentary	Discusses the double burden synergies of Influenza and COVID 19 in the Global South, and proposes how a way to address both issues.
31	Saksena N. Global justice and the COVID-19 vaccine: Limitations of the public goods framework. <i>Global Public Health</i> 2021	Article	Focuses on global access, discussing the limitations of the global public good framework in addressing the problem of distribution COVID-19 vaccines.
32	Sawal I, Ahmad S, Tariq W, et al. Unequal distribution of COVID-19 vaccine: A looming crisis. <i>Journal of Medical Virology</i> 2021;03:03.	Letter to Editor	Argues for the promotion of equitable access to COVID-19 vaccines to benefit the whole world.
33	Sharma S, Kawa N, Gomber A. WHO's allocation framework for COVAX: is it fair? <i>Journal of Medical Ethics</i> 2021;09:09.	Article	Explores comparing COVAX allocation mechanisms to a targeted allocation system, based on need. Arguing that this could maximize well-being and align with principles of equity.
34	Sehovic AB, Govender K. Addressing COVID-19 vulnerabilities: How do we achieve global health security in an inequitable world. <i>Global Public Health</i> 2021	Commentary	Discusses the particular challenges of COVID-19 for LMICs, and the inequities being perpetuated in the COVID-19 Pandemic and the suggestions in how to address these challenges.
35	So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. <i>Bmj-British Medical Journal</i> 2020;371	Special paper	Analyzes premarket purchase commitments for COVID-19 vaccines from leading manufacturers to recipient countries.
36	So AD, Woo J. Achieving path-dependent equity for global COVID-19 vaccine allocation. <i>Medicina Intensiva</i> 2021;2(4):373-77.	Commentary	Discusses the interdependence of equitable allocation based on three policy levers: Development and Production, Procurement, and Healthcare Delivery.
37	Torres I, Artaza O, Profeta B, et al. COVID-19 vaccination: returning to WHO's Health For All. <i>The Lancet Global Health</i> 2020;8(11):e1355-e56.	Commentary	Promotes the perspective of World Health Organization, calling for inclusion of all member states, and transparency.
38	Towse A, Chalkidou K, Firth I, et al. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? <i>Value in Health</i> 2021;24(5):625-31.	Article	Proposes the Benefit-Based Advance Market Commitment as a collaborative, market-based financing mechanism for the world to incentivize and pay for the development and provide equitable access to second and third generation COVID-19 vaccines.
39	Turner M. Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009-H1N1. <i>Glob Public Health</i> 2016;11(3):322-35.	Article	A case study on the procurement of pandemic influenza vaccines during 2009-H1N1, and the likely manner in which procurement will occur during future pandemics.
40	Usher AD. COVID-19 vaccines for all? <i>Lancet (London, England)</i> 2020;395(10240):1822-23.	World report	Provides an assessment of the initiatives being planned to ensure equitable access to COVID-19 vaccines, and shortcomings.
41	Usher AD. CEPI criticised for lack of transparency. <i>Lancet</i> 2021;397(10271):265-66.	World Report	Provides insights and perspectives on CEPI contracts for COVID-19 vaccines.
42	Usher AD. South Africa and India push for COVID-19 patents ban. <i>Lancet</i> 2020;396(10265):1790-91.	World Report	Report on the proposal by India and South Africa to waiver Intellectual Property Rights to COVID-19 products (incl. vaccines).
43	Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. <i>Lancet</i> 2021;397(10278):1023-34.	Article	Reviews potential challenges and policy implications for the production, affordable pricing, and global allocation of Covid-19 vaccines.
44	Yamey G, Schäferhoff M, Hatchett R, et al. Ensuring global access to COVID-19 vaccines. <i>Lancet (London, England)</i> 2020;395(10234):1405-06.	Commentary	Discusses how COVID-19 vaccines can be used globally to end the COVID-19 pandemic, arguing for three imperatives: speed, manufacture and deployment at scale, and global access.